Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.

IF 5 2区医学 Q2 IMMUNOLOGY

Journal of Infectious Diseases Pub Date : 2024-12-16 DOI:10.1093/infdis/jiae303

Jingrong Ye, Yuan Dong, Yun Lan, Jing Chen, Ying Zhou, Jinjin Liu, Dan Yuan, Xinli Lu, Weigui Guo, Minna Zheng, Hong Yang, Xiao Song, Cong Liu, Quanhua Zhou, Chenli Zheng, Qi Guo, Xiaohui Yang, Lincai Zhang, Zhangwen Ge, Lifeng Liu, Fengting Yu, Yang Han, Huihuang Huang, Mingqiang Hao, Yuhua Ruan, Jianjun Wu, Jianjun Li, Qiang Chen, Zhen Ning, Xuemei Ling, Chang Zhou, Xuangu Liu, Jianyun Bai, Ya Gao, Xue Tong, Kangping Zhou, Fanghua Mei, Zhengrong Yang, Ao Wang, Wei Wei, Ruijuan Qiao, Xinhua Luo, Xiaojie Huang, Juan Wang, Xin Shen, Fengyu Hu, Linglin Zhang, Wei Tan, Jixiang Fan, Aixia Tu, Guolong Yu, Yong Fang, Shufang He, Xin Chen, Donglin Wu, Xinhui Zhang, Ruolei Xin, Xin He, Xianlong Ren, Conghui Xu, Yanming Sun, Yang Li, Guowu Liu, Xiyao Li, Junyi Duan, Tao Huang, Yiming Shao, Yi Feng, Qichao Pan, Bin Su, Tianjun Jiang, Hongxin Zhao, Tong Zhang, Faqing Chen, Bing Hu, Hui Wang, Jin Zhao, Kun Cai, Wei Sun, Baicheng Gao, Tielin Ning, Shu Liang, Yuqi Huo, Gengfeng Fu, Feng Li, Yi Lin, Hui Xing, Hongyan Lu

{"title":"Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.","authors":"Jingrong Ye, Yuan Dong, Yun Lan, Jing Chen, Ying Zhou, Jinjin Liu, Dan Yuan, Xinli Lu, Weigui Guo, Minna Zheng, Hong Yang, Xiao Song, Cong Liu, Quanhua Zhou, Chenli Zheng, Qi Guo, Xiaohui Yang, Lincai Zhang, Zhangwen Ge, Lifeng Liu, Fengting Yu, Yang Han, Huihuang Huang, Mingqiang Hao, Yuhua Ruan, Jianjun Wu, Jianjun Li, Qiang Chen, Zhen Ning, Xuemei Ling, Chang Zhou, Xuangu Liu, Jianyun Bai, Ya Gao, Xue Tong, Kangping Zhou, Fanghua Mei, Zhengrong Yang, Ao Wang, Wei Wei, Ruijuan Qiao, Xinhua Luo, Xiaojie Huang, Juan Wang, Xin Shen, Fengyu Hu, Linglin Zhang, Wei Tan, Jixiang Fan, Aixia Tu, Guolong Yu, Yong Fang, Shufang He, Xin Chen, Donglin Wu, Xinhui Zhang, Ruolei Xin, Xin He, Xianlong Ren, Conghui Xu, Yanming Sun, Yang Li, Guowu Liu, Xiyao Li, Junyi Duan, Tao Huang, Yiming Shao, Yi Feng, Qichao Pan, Bin Su, Tianjun Jiang, Hongxin Zhao, Tong Zhang, Faqing Chen, Bing Hu, Hui Wang, Jin Zhao, Kun Cai, Wei Sun, Baicheng Gao, Tielin Ning, Shu Liang, Yuqi Huo, Gengfeng Fu, Feng Li, Yi Lin, Hui Xing, Hongyan Lu","doi":"10.1093/infdis/jiae303","DOIUrl":null,"url":null,"abstract":"Background: National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies.Methods: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations.Results: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1-4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%-2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%-1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%-1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%-4.52%) in 2018 to 5.39% (95% CI, 4.33%-6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%-.38%) of 4205 PWH.Conclusions: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":"1410-1421"},"PeriodicalIF":5.0000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiae303","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies.

Methods: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations.

Results: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1-4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%-2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%-1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%-1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%-4.52%) in 2018 to 5.39% (95% CI, 4.33%-6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%-.38%) of 4205 PWH.

Conclusions: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.

查看原文本刊更多论文

2018年至2023年中国艾滋病传播耐药性的趋势和模式。

背景：随着中国国家治疗指南的不断发展，有必要对人群进行耐药性监测：中国不断发展的国家治疗指南要求对传播耐药性（TDR）进行人群水平的监测，以便为艾滋病治疗策略提供信息或更新治疗策略：我们分析了居住在中国 31 个省份、2018 年至 2023 年间新确诊的 HIV 感染者（PWH）的人口统计学、临床和病毒学数据。TDR证据由世界卫生组织耐药突变监测清单定义：在22 124名具有蛋白酶和逆转录酶序列的PWH中，965人（4.36%；95% CI，4.1-4.63）至少有1个TDR突变。最常见的TDR突变是非核苷类逆转录酶抑制剂（NNRTI）突变（2.39%；95% CI，2.19%-2.59%），其次是核苷类逆转录酶抑制剂突变（1.35%；95% CI，1.2%-1.5%）和蛋白酶抑制剂突变（1.12%；95% CI，0.98%-1.26%）。蛋白酶和逆转录酶总TDR从2018年的4.05%（95% CI，3.61%-4.52%）大幅增至2023年的5.39%（95% CI，4.33%-6.57%）。在 4205 例 PWH 中，有 9 例（0.21%；95% CI，.1%-.38%）检测到低水平的整合酶链转移抑制剂 TDR：目前，继续使用以 NNRTI 为基础的一线抗逆转录病毒疗法治疗艾滋病是合理的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infectious Diseases 医学-传染病学

CiteScore

13.50

自引率

3.10%

发文量

449

审稿时长

2-4 weeks

期刊介绍： Published continuously since 1904, The Journal of Infectious Diseases (JID) is the premier global journal for original research on infectious diseases. The editors welcome Major Articles and Brief Reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. JID is an official publication of the Infectious Diseases Society of America.